BACKGROUND: Cardiotoxicity after cancer treatment is a potentially preventable life-threatening complication among women with breast cancer. There is no algorithm to identify women with breast cancer at risk of cardiotoxicity. OBJECTIVES: We quantified signs and symptoms as well as selected laboratory values among women with breast cancer who developed cardiotoxicity. METHODS: The clinical characteristics (n = 15) were collected from electronic health records. Spearman correlation coefficients and a nonparametric statistical test were used to analyze data. RESULTS: Significant statistical differences were detected in the laboratory values comparing the first and second half of 6 months before cardiotoxicity including alanine aminotransferase (U/L) (30.67 ± 26.27 and 42.31 ± 35.65, respectively; P = .03, Cohen's d = 0.37). A negative correlation was found between estimated glomerular filtration rate and new onset of more than 1 sign or symptom (Spearman's ρ = -0.5, P = .06). CONCLUSIONS: Investigating clinical characteristics before cardiotoxicity may determine the mechanism(s) and identify high-risk patients.
BACKGROUND: Cardiotoxicity after cancer treatment is a potentially preventable life-threatening complication among women with breast cancer. There is no algorithm to identify women with breast cancer at risk of cardiotoxicity. OBJECTIVES: We quantified signs and symptoms as well as selected laboratory values among women with breast cancer who developed cardiotoxicity. METHODS: The clinical characteristics (n = 15) were collected from electronic health records. Spearman correlation coefficients and a nonparametric statistical test were used to analyze data. RESULTS: Significant statistical differences were detected in the laboratory values comparing the first and second half of 6 months before cardiotoxicity including alanine aminotransferase (U/L) (30.67 ± 26.27 and 42.31 ± 35.65, respectively; P = .03, Cohen's d = 0.37). A negative correlation was found between estimated glomerular filtration rate and new onset of more than 1 sign or symptom (Spearman's ρ = -0.5, P = .06). CONCLUSIONS: Investigating clinical characteristics before cardiotoxicity may determine the mechanism(s) and identify high-risk patients.
Authors: C F Spraggs; L R Parham; L P Briley; L Warren; L S Williams; D J Fraser; Z Jiang; Z Aziz; S Ahmed; G Demetriou; A Mehta; N Jackson; J Byrne; M Andersson; M Toi; L Harris; J Gralow; J A Zujewski; R Crescenzo; A Armour; E Perez; M Piccart Journal: Pharmacogenomics J Date: 2017-08-08 Impact factor: 3.550
Authors: Hari K Narayan; Brian Finkelman; Benjamin French; Theodore Plappert; David Hyman; Amanda M Smith; Kenneth B Margulies; Bonnie Ky Journal: Circulation Date: 2017-01-19 Impact factor: 29.690
Authors: Amy A Kirkham; Rhys I Beaudry; D Ian Paterson; John R Mackey; Mark J Haykowsky Journal: Prog Cardiovasc Dis Date: 2019-02-22 Impact factor: 8.194
Authors: Siddhartha Yadav; Dhauna Karam; Irbaz Bin Riaz; Hao Xie; Urshila Durani; Narjust Duma; Karthik V Giridhar; Tina J Hieken; Judy C Boughey; Robert W Mutter; John R Hawse; Rafael E Jimenez; Fergus J Couch; Roberto A Leon-Ferre; Kathryn J Ruddy Journal: Cancer Date: 2019-10-07 Impact factor: 6.860
Authors: Helen Strongman; Sarah Gadd; Anthony Matthews; Kathryn E Mansfield; Susannah Stanway; Alexander R Lyon; Isabel Dos-Santos-Silva; Liam Smeeth; Krishnan Bhaskaran Journal: Lancet Date: 2019-08-20 Impact factor: 202.731
Authors: Jose Luis Zamorano; Patrizio Lancellotti; Daniel Rodriguez Muñoz; Victor Aboyans; Riccardo Asteggiano; Maurizio Galderisi; Gilbert Habib; Daniel J Lenihan; Gregory Y H Lip; Alexander R Lyon; Teresa Lopez Fernandez; Dania Mohty; Massimo F Piepoli; Juan Tamargo; Adam Torbicki; Thomas M Suter Journal: Eur Heart J Date: 2016-08-26 Impact factor: 29.983